In today’s episode, we welcome Principal Researcher Dr. David Tamborero who was integral to the development of the Molecular Tumor Board Portal to discuss the benefits associated with molecular tumor boards and the way in which the portal can support the discussions that take place at tumor board meetings, as well as how these initiatives can support the management of patients with thyroid cancer.

References

1. Larson KL et al. Clinical Outcomes of Molecular Tumor Boards: A Systematic Review.  
   JCO Precis Oncol 2021;5:PO.20.00495
2. Capdevila J et al. Molecular diagnosis and targeted treatment of advanced follicular  
   cell-derived thyroid cancer in the precision medicine era. Cancer Treat Rev 2022;106:102380
3. Mahmood U and Lorch JH. Precision Medicine in Aggressive Thyroid Cancer: Moving Beyond Multitargeted Tyrosine Kinase Inhibitors. Cancer Cytopathol 2022;130:8–11
4. VanderWalde A et al. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. J Pers Med 2020;10:252
5. Tamborero D et al. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer 2022;3:251–261

Target Audience:

Oncologists, pathologists and other HCPs involved in the diagnosis of RET and TRK cancers, with a focus on community practitioners.

Learning Objective:

1. Recall thyroid RET and TRK fusion-positive cancer diagnosis and relevant genomic testing guidelines and identify ways to adapt the guidelines to local settings
2. Discuss “precision medicine” and new technologies, including “liquid biopsy”
3. Review the organisation of care and strategies for more efficient care delivery

These learning objectives are for the podcast series. This episode focuses on the second and third objective.

Funding Information:

This episode is supported by an educational grant from Eli Lilly, who have had no influence on the content or choice of faculty.

Staff Disclosure:

Dr. David Tamborero has no relevant disclosures to announce